Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor α, NFKB1, and peroxisome proliferator-activated receptor γ with colorectal cancer

Cancer Research

Volumn 63, Issue 13, 2003, Pages 3560-3566

  Landi, Stefano ^a,b   Moreno, Victor ^c   Gioia Patricola, Lydie ^a   Guino, Elisabeth ^c   Navarro, Matilde ^c   De Oca, Javier ^d   Capella, Gabriel ^c   Canzian, Federico ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b UNIVERSITY OF PISA   (Italy)

^c CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; INFLAMMATION; INTRON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SPAIN;

AGED; CASE-CONTROL STUDIES; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; FEMALE; GENOTYPE; HUMANS; INFLAMMATION; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECTAL NEOPLASMS; RISK FACTORS; SPAIN; TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0038079807     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Hart, J. Inflammation. I: its role in the healing of acute wounds. J. Wound Care, 11: 205-209, 2002.
2. Ley, K. Pathways and bottlenecks in the web of inflammatory adhesion molecules and chemoattractants. Immunol. Res., 24: 87-95, 2001.
3. Elenkov, I. J., and Chrousos, G. P. Stress hormones, proinflammatory and anti-inflammatory cytokines, and autoimmunity. Ann. N. Y. Acad, Sci., 966: 290-303, 2002.
4. Ludewig, B., Zinkernagel, R. M., and Hengartner, H. Arterial inflammation and atherosclerosis. Trends Cardiovasc. Med., 12: 154-159, 2002.
5. Perry, V. H., Bolton, S. J., Anthony, D. C., and Betmouni, S. The contribution of inflammation to acute and chronic neurodegeneration. Res. Immunol., 149: 721-725, 1998.
6. Shacter, E., and Weitzman, S. A. Chronic inflammation and cancer. Oncology, 16: 217-226, 2002.
7. Malkinson, A. M., Bauer, A., Meyer, A., Dwyer-Nield, L., Koski, K., Keith, R., Geraci, M., and Miller, Y. Experimental evidence from an animal model of adenocarcinoma that chronic inflammation enhances lung cancer risk. Chest, 117 (5 Suppl. 1): 228S, 2000.
8. Mayne, S. T., Buenconsejo, J., and Anderich, D. T. Previous lung disease and risk of lung cancer among men and women nonsmokers. Am. J. Epidemiol., 149: 13-20, 1999.
9. Badawi, A. F., Mostafa, M. H., Probert, A., and O'Connor, P. J. Role of schistosomiasis in human bladder cancer: evidence of association, aetiological factors, and basic mechanisms of carcinogenesis. Eur. J. Cancer Prev., 4: 45-59, 1995.
10. Manning, C. B., Vallyathan, V., and Mossman, B. T. Diseases caused by asbestos: mechanisms of injury and disease development. Int. Immunopharmacol., 2: 191-200, 2002.
11. McCann, J. Esophageal cancers: changing character, increasing incidence. J. Natl. Cancer Inst. (Bethesda), 91: 497-498, 1999.
12. Williams, M. P., and Pounder, R. E. Helicobacter pylori: from the benign to the malignant. Am. J. Gastroenterol., 94: S11-S16, 1999.
13. Farrell, R. J., and Peppercorn, M. A. Ulcerative colitis. Lancet, 359: 331-340, 2002.
14. Rhodes, J. M., and Campbell, B. J. Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared. Trends Mol. Med., 8: 10-16, 2002.
15. Higaki, S., Akazawa, A., Nakamura, H., Yanai, H., Yoshida, T., and Okita, K. Metaplastic polyp of the colon develops in response to inflammation. J. Gastroenterol. Hepatol., 14: 709-714, 1999.
16. Jackson, J. R., Seed, M. P., Kircher, C. H., Willoughby, D. A., and Winkler, J. D. The codependence of angiogenesis and chronic inflammation. FASEB J., 11: 457-465, 1997.
17. Phoa, N., and Epe, B. Influence of nitric oxide on the generation and repair of oxidative DNA damage in mammalian cells. Carcinogenesis (Lond.), 23: 469-475, 2002.
18. Jaiswal, M., LaRusso, N. F., Burgart, L. J., and Gores, G. J. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res., 60: 184-190, 2000.
19. Moore, M. A. Cytokine and chemokine networks influencing stem cell proliferation, differentiation, and marrow homing. J. Cell. Biochem., 38 (Suppl.): 29-38, 2002.
20. Nakajima, N., Kuwayama, H., Ito, Y., Iwasaki, A., and Arakawa, Y. Helicobacter pylori, neutrophils, interleukins, and gastric epithelial proliferation. J. Clin. Gastroenterol., 25 (Suppl. 1): S198-S202, 1997.
21. Eberhart, C. E., Coffey, R. J., Radhika, A., Giardiello, F. M., Ferrenbach, S., and DuBois R. N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 107: 1183-1188, 1994.
22. IARC, Non-steroidal anti-inflammatory drugs. IARC Handbooks of Cancer Prevention, Vol. 1. Lyon, France: IARC Press, 1997.
23. Qureshi, S. T., Gros, P., and Malo, D. The Lps locus: genetic regulation of host responses to bacterial lipopolysaccharide. Inflamm. Res., 48: 613-620, 1999.
24. Watson, A. J. M., and Pritchard, D. M. Lessons from genetically engineered animal models VII. Apoptosis in intestinal epithelium: lessons from transgenic and knockout mice. Am. J. Physiol., 278: G1-G5, 2000.
25. Hudson, J. D., Shoaibi, M. A., Maestro, R., Carnero, A., Hannon, G. J., and Beach, D. H. A. proinflammatory cytokine inhibits p53 tumor suppressor activity. J. Exp. Med., 190: 1375-1382, 1999.
26. Keshavarzian, A., Fusunyan, R. D., Jacyno, M., Winship, D., MacDermott, R. P., and Sanderson, I. R. Increased interleukin-8 (IL-8) in rectal dialysate from patients with ulcerative colitis: evidence for a biological role for IL-8 in inflammation of the colon. Am. J. Gastroenterol., 94: 704-712, 1999.
27. Nusrat, A., Sitaraman, S. V., and Neish, A. Interaction of bacteria and bacterial toxins with intestinal epithelial cells. Curr. Gastroenterol. Rep., 3: 392-398, 2001.
28. Stumvoll, M., and Haring, H. Insulin resistance and insulin sensitizers. Horm. Res., 55 (Suppl. 2): 3-13, 2001.
29. Wada, K., Nakajima, A., and Blumberg R. S. PPARγ and inflammatory bowel disease: a new therapeutic target for ulcerative colitis and Crohn's disease. Trends Mol. Med., 7: 329-331, 2001.
30. Chinetti, G., Fruchart, J. C., and Staels, B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm. Res., 49: 497-505, 2000.
31. Sarraf, P., Mueller, E., Smith, W. M., Wright, H. M., Kum, J. B., Aaltonen, L. A., de la Chapelle, A., Spiegelman, B. M., and Eng, C. Loss-of-function mutations in PPAR γ associated with human colon cancer. Mol. Cell, 3: 799-804, 1999.
32. Kitamura, S., Miyazaki, Y., Shinomura, Y., Kondo, S., Kanayama, S., and Matsuzawa, Y. Peroxisome proliferator-activated receptor γ induces growth arrest and differentiation markers of human colon cancer cells. Jpn. J. Cancer Res., 90: 75-80, 1999.
33. Tanaka, T., Kohno, H., Yoshitani, S., Takashima, S., Okumura, A., and Murakami, A. Ligands for peroxisome proliferator-activated receptors α and γ inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res., 61: 2424-2428, 2001.
34. Fishman, D., Faulds, G., Jeffery, R., Mohamed-Ali, V., Yudkin, J. S., Humphries, S., and Woo, P. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J. Clin. Investig., 102: 1369-1376, 1998.
35. Terry, C. F., Loukaci, V., and Green, F. R. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J. Biol. Chem., 275: 18138-18144, 2000.
36. Vickers, M. A., Green, F. R., Terry, C., Mayosi, B. M., Julier, C., Lathrop, M., Ratcliffe, P. J., Watkins, H. C., and Keavney, B. Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein. Cardiovasc. Res., 53: 1029-1034, 2002.
37. Brull, D. J., Montgomery, H. E., Sanders, J., Dhamrait, S., Luong, L., Rumley, A., Lowe, G. D., and Humphries, S. E. Interleukin-6 gene -174g>c and -572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler. Thromb. Vasc. Biol., 21: 1458-1463, 2001.
38. Haukim, N., Bidwell, J. L., Smith, A. J., Keen, L. J., Gallagher, G., Kimberly, R., Huizinga, T., McDermott, M. F., Oksenberg, J., McNicholl, J., Pociot, F., Hardt, C., and D'Alfonso, S. Cytokine gene polymorphism in human disease: on-line databases, supplement 2. Genes Immun., 3: 313-330, 2002.
39. Jones, K. G., Brull, D. J., Brown, L. C., Sian, M., Greenhalgh, R. M., Humphries, S. E., and Powell, J. T. Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms. Circulation, 103: 2260-2265, 2001.
40. Humphries, S. E., Luong, L. A., Ogg, M. S., Hawe, E., and Miller, G. J. The interleukin-6-174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur. Heart J., 22: 2243-2252, 2001.
41. Foster, C. B., Lehrnbecher, T., Samuels, S., Stein, S., Mol, F., Metcalf, J. A., Wyvill, K., Steinberg, S. M., Kovacs, J., Blauvelt, A., Yarchoan, R., and Chanock, S. J. An IL-6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus. Blood, 96: 2562-2567, 2000.
42. Wilson, A. G., Symons, J. A., McDowell, T. L., McDevitt, H. O., and Duff, G. W. Effects of a polymorphism in the human tumor necrosis factor α promoter on transcriptional activation. Proc. Natl. Acad. Sci. USA, 94: 3195-3199, 1997.
43. Hull, J., Thomson, A., and Kwiatkowski, D. Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax, 55: 1023-1027, 2000.
44. Zhou, X. P., Smith, W. M., Gimm, O., Mueller, E., Gao, X., Sarraf, P., Prior, T. W., Plass, C., von Deimling, A., Black, P. M., Yates, A. J., and Eng, C. Over-representation of PPARγ sequence variants in sporadic cases of glioblastoma multiforme: preliminary evidence for common low penetrance modifiers for brain tumour risk in the general population. J. Med. Genet., 37: 410-414, 2000.
45. Fajas, L., Auboeuf, D., Raspe, E., Schoonjans, K., Lefebvre, A. M., and Saladin, R. The organization, promoter analysis, and expression of the human PPARγ gene. J. Biol. Chem., 272: 18779-18789, 1997.
46. Altshuler, D., Hirschhorn, J. N., Klannemark, M., Lindgren, C. M., Vohl, M. C., Nemesh, J., Lane, C. R., Schaffner, S. F., Bolk, S., Brewer, C., Tuomi, T., Gaudet, D., Hudson, T. J., Daly, M., Groop, L., and Lander, E. S. The common PPARγ Pro-2A1a polymorphism is associated with decreased risk of type 2 diabetes. Nat. Genet., 26: 76-80, 2000.
47. Deeb, S. S., Fajas, L., Nemoto, M., Pihlajamaki, J., Mykkanen, L., Kuusisto, J., Laakso, M., Fujimoto, W., and Auwerx, J. A. Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat. Genet., 20: 284-287, 1998.
48. Smith, W. M., Zhou, X. P., Kurose, K., Gao, X., Latif, F., Kroll, T., Sugano, K., Cannistra, S. A., Clinton, S. K., Maher, E. R., Prior, T. W., and Eng, C. Opposite association of two PPARG variants with cancer: overrepresentation of H449H in endometrial carcinoma cases and underrepresentation of P12A in renal cell carcinoma cases. Hum. Genet., 109: 146-151, 2001.
49. Garte, S., Gaspari, L., Alexandrie, A. K., Ambrosone, C., Autrup, H., Autrup, J. L., Baranova, H., Bathum, L., Benhamou, S., Boffetta, P., Bouchardy, C., Breskvar, K., Brockmoller, J., Cascorbi, I., Clapper, M. L., Coutelle, C., Daly, A., Dell'Omo, M., Dolzan, V., Dresler, C. M., Fryer, A., Haugen, A., Hein, D. W., Hildesheim. A., Hirvonen, A., Hsieh, L. L., Ingelman-Sundberg, M., Kalina, I., Kang, D., Kihara, M., Kiyohara, C., Kremers, P., Lazarus, P., Le, Marchand, L., Lechner. M. C., van, Lieshout, E. M., London, S., Manni, J. J., Maugard, C. M., Morita, S., Nazar-Stewart, V., Noda, K., Oda, Y., Parl, F. F., Pastorelli, R., Persson, I., Peters, W. H., Rannug, A., Rebbeck, T., Risch, A., Roelandt, L., Romkes, M., Ryberg, D., Salagovic, J., Schoket, B., Seidegard, J., Shields, P. G., Sim, E., Sinnet, D., Strange, R. C., Stucker, I., Sugimura, H., To-Figueras, J., Vineis, P., Yu, M. C., and Taioli, E. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol. Biomark. Prev., 10: 1239-1248, 2001.
50. EPIC Group of Spain. Relative validity and reproducibility of a diet history questionnaire in Spain. I. Foods. EPIC Group of Spain. European Prospective Investigation into Cancer and Nutrition. Int. J. Epidemiol., 26 (Suppl. 1): S91-S99, 1997.
51. EPIC Group of Spain. Relative validity and reproducibility of a diet history questionnaire in Spain. I. Nutrients. EPIC Group of Spain. European Prospective Investigation into Cancer and Nutrition. Int. J. Epidemiol., 26 (Suppl. 1): S100-S109, 1997.
52. Rothman, K. J. No adjustments are needed for multiple comparisons. Epidemiology, 1: 43-46, 1990.
53. Rachmilewitz, D., Simon, P. L., Schwartz, L. W., Griswold, D. E., Fondacaro, J. D., and Wasserman, M. A. Inflammatory mediators of experimental colitis in rats. Gastroenterology, 97: 326-337, 1989.
54. Franceschi, S., and La Vecchia, C. Alcohol and the risk of cancers of the stomach and colon-rectum. Dig. Dis., 12: 276-289, 1994.
55. Kaaks, R., Toniolo, P., Akhmedkhanov, A., Lukanova, A., Biessy, C., and Dechaud, H. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J. Natl. Cancer Inst. (Bethesda), 92: 1592-1600, 2000.
56. Elstner, E., Muller, C., Koshizuka, K., Williamson. E. A., Park, D., Asou, H., Shintaku, P., Said, J. W., Heber, D., and Koeffler, H. P. Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl. Acad. Sci. USA, 95: 8806-8811, 1998.
57. Sarraf, P., Mueller, E., Jones, D., King, F. J., DeAngelo, D. J., Partridge, J. B., Holden, S. A., Chen, L. B., Singer, S., Fletcher, C., and Spiegelman, B. M. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat. Med., 4: 1046-1052, 1998.
58. Kubota, T., Koshizuka, K., Williamson, E. A., Asou, H., Said, J. W., Holden, S., Miyoshi, I., and Koeffler, H. P. Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res., 58: 3344-3352, 1998.
59. Tsubouchi, Y., Sano, H., Kawahito, Y., Mukai, S., Yamada, R., Kohno, M., Inoue, K., Hla, T., and Kondo, M. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-γ agonists through induction of apoptosis. Biochem. Biophys. Res. Commun., 270: 400-405, 2000.
60. Toyota, M., Miyazaki, Y., Kitamura, S., Nagasawa, Y., Kiyohara, T., Shinomura, Y., and Matsuzawa, Y. Peroxisome proliferator-activated receptor γ reduces the growth rate of pancreatic cancer cells through the reduction of cyclin D1. Life Sci., 70: 1565-1575, 2002.
61. Heim, M., Johnson, J., Boess, F., Bendik, I., Weber, P., Hunziker, W., and Fluhmann, B. Phytanic acid, a natural peroxisome proliferator-activated receptor (PPAR) agonist, regulates glucose metabolism in rat primary hepatocytes. FASEB J., 16: 718-720, 2002.
62. Ramji, D. P., Vitelli, A., Tronche, F., Cortese, R., and Ciliberto, G. The two C/EBP isoforms. IL-6DBP/NF-IL6 and C/EBP delta/NF-IL6 β, are induced by IL-6 to promote acute phase gene transcription via different mechanisms. Nucleic Acids Res., 21: 289-294, 1993.
63. Gabay, C., Gigley, J., Sipe, J., Arend, W. P., and Fantuzzi, G. Production of IL-1 receptor antagonist by hepatocytes is regulated as an acute-phase protein in vivo. Eur. J. Immunol., 31: 490-499, 2001.
64. Pritts, T., Hungness, E., Wang, Q., Robb, B., Hershko, D., and Hasselgren, P. O. Mucosal and enterocyte IL-6 production during sepsis and endotoxemia-role of transcription factors and regulation by the stress response. Am. J. Surg., 183: 372-383, 2002.
65. Motro, B., Itin, A., Sachs, L., and Keshet, E. Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. Proc. Natl. Acad. Sci. USA. 87: 3092-3096, 1990.
66. Hatzi, E., Murphy, C., Zoephel, A., Rasmussen, H., Morbidelli, L., Ahorn, H., Kunisada, K., Tontsch, U., Klenk, M., Yamauchi-Takihara, K., Ziche, M., Rofstad, E. K., Schweigerer, L., and Fotsis, T. N-Myc oncogene overexpression downregulates IL-6; evidence that IL-6 inhibits angiogenesis and suppresses neuroblastoma tumor growth. Oncogene, 21: 3552-3561, 2002.
67. Park, K. S., Mok, J. W., Rho, S. A., and Kim, J. C. Analysis of TNFB and TNFA NcoRFLP in colorectal cancer. Mol. Cell, 8: 246-249, 1998.
68. Jang, W. H., Yang, Y. I., Yea, S. S., Lee, Y. J., Chun, J. H., Kim, H. I., Kim, M. S., and Paik, K. H. The -238 tumor necrosis factor-α promoter polymorphism is associated with decreased susceptibility to cancers. Cancer Lett., 166: 41-46, 2001.
69. Saito, S., Kasai, Y., Nomoto, S., Fujiwara, M., Akiyama, S., Ito, K., and Nakao, A. Polymorphism of tumor necrosis factor in esophageal, gastric or colorectal carcinoma. Hepatogastroenterology, 48: 468-470, 2001.
70. Martin, E. R., Lai, E. H., Gilbert, J. R., Rogala, A. R., Afshari, A. J., Riley, J., Finch, K. L., Stevens, J. F., Livak, K. J., Slotterbeck, B. D., Slifer, S. H., Warren, L. L., Conneally, P. M., Schmechel, D. E., Purvis, I., Pericak-Vance, M. A., Roses, A. D., and Vance, J. M. SNPing away at complex diseases: analysis of single-nucleotide polymorphisms around APOE in Alzheimer disease. Am. J. Hum. Genet., 67: 383-394, 2000.